From: Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis
Group 1 | Group 2 | t | P | |
---|---|---|---|---|
FVC (ml) | 1287.6 ± 106.79 | 1276.0 ± 106.74 | 0.344 | 0.733 |
FVC% predicted | 55.75 ± 4.26 | 57.45 ± 6.16 | 0.200 | 0.842 |
6MWT (m) | 287.5 ± 33.06 | 290.0 ± 28.383 | − 0.255 | 0.800 |
PaO2 at rest(mmHg) | 64.75 ± 2.31 | 62.85 ± 4.24 | − 1.892 | 0.121 |
SaO2 | 93.5 ± 2.48 | 92.5 ± 2.63 | − 1.792 | 0.142 |
Estimated PAP | 35.0 ± 5.36 | 33.25 ± 7.74 | 1.795 | 0.081 |
SGRQ SCORE | 37.2 ± 1.43 | 37.85 ± 2.42 | − 0.995 | 0.326 |
FVC (ml) 6 M | 1265.55 ± 215.15 | 1100.5 ± 109.46 | 4.031 | 0.00** |
FVC% predicted 6 M | 48.85 ± 6.42 | 44.5 ± 4.53 | 3.231 | 0.002* |
6MWT 6 M | 310.0 ± 74.09 | 267.0 ± 37.98 | 2.356 | 0.028* |
PAP 6 M | 33.0 ± 6.56 | 36.8 ± 5.95 | − 2.186 | 0.037* |
SaO2 6 M | 94.15 ± 3.52 | 87.0 ± 3.07 | 2.745 | 0.017* |
PaO2 6 M | 66.05 ± 2.81 | 54.9 ± 3.53 | 10.113 | 0.00** |
SGRQ SCORE 6M | 38.25 ± 2.35 | 44.5 ± 4.52 | 6.789 | 0.00** |